PBMs made more than $7B marking up specialty generics

Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
PBMs Generated Billions in Drug Markups, FTC Says
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
PBMs made more than $7B marking up specialty generics: FTC
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade Commission charged on Tuesday.
FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for patients and health plan sponsors.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through vertical integration,
Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
FTC Launches Inquiry of Single-Family Rental Home 'Mega Investors,' Issues PBM Report
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
STAT5h
Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
pharmaphorum7h
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...
ConsumerAffairs7h
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of ...
Benefits Pro1d
Sen. Warren brings bipartisan team back for more action against PBMs
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
Butler County Times Gazette3d
The PBM monopolies and how they affect pharmacies in Butler County
As many as 10 family-owned or pharmacies faced closure each day around the United States of America in 2024. This isn’t due ...